Acute Myeloid Leukemia Market Sees Precision-Fueled Growth

AML Treatment: A Primer on the Changing Landscape

Abstract: As the global incidence of AML rises, the horizon of treatment options has expanded from chemotherapy and stem cell transplant to targeted therapy, novel formulations, and the role of companion diagnostics.

Acute myeloid leukemia (AML) is a highly aggressive cancer that arises in the bone marrow and has remained largely unchanged since its first reported incidence in the early 1800s. AML is most common in older adults, and despite several decades of research, mortality remains elevated and treatment options are still limited.

While many other cancers have experienced substantial progress over the last two decades, It is anticipated that new treatments will result in better patient outcomes, quality of life, and survival rates for AML.

What’s Driving Demand?

AML’s evolution into precision medicine is largely driven by unmet medical need, which manifests in two key ways. First, the median age of diagnosis is in the late 60s. Second, among patients who are ineligible for intensive chemotherapy and stem cell transplant, the disease can be particularly challenging to treat. As the only curative option, stem cell transplant has historically resulted in severe adverse events. However, emerging therapeutic options are overcoming these challenges and transforming the outlook for the disease.

Beyond these key drivers, additional factors are propelling growth in the AML treatment market:

Increased Global Prevalence

Aging demographics, improvements in diagnostic testing, and greater screening efforts have contributed to the rising incidence of AML.

Accelerated Regulatory Approvals

The FDA and EMA have made significant changes to expedite novel AML treatment options. These changes include grantings of Orphan Drug Designation and Breakthrough Therapy Status, leading to accelerated approvals.

Investment and R&D

Industry players are actively developing targeted therapy options and companion diagnostics to match the right therapy to each patient’s AML profile.

Get Sample Pages at https://www.theresearchinsights.com/request_sample?id=31

Expanded Adoption of NGS

In 2017, the American Society of Clinical Oncology and the American Society of Hematology endorsed NGS as a recommended standard for identifying the genomic basis of cancer. Now, the implementation of NGS is rapidly gaining traction, facilitating early detection of treatable genetic mutations.

ML Treatment Trends

Research, including that of the California Breast Cancer, Melanoma, Colorectal, and Prostate Cancer Consortia, and the Mayo Clinic, has shown that genetic and epigenetic biomarkers are key determinants of response. These findings support the adoption of combination therapy to extend patient lives. These studies also shed light on the challenges faced in treating the disease, such as the development of drug resistance, which presents a barrier to extended remission.

New Technologies for Treating AML

In addition to targeted therapies, combination therapies, and newer formulations, a growing body of evidence is indicating the benefits of monitoring minimal residual disease (MRD). Furthermore, companies are seeking to facilitate treatment by reducing patient burden, monitoring at home, and telehealth offerings.

Geographical Trends

Historically, the U.S. was the largest market for AML, with its high health expenditure and strong investment in research. However, the market is expected to see rapid growth in the Asia-Pacific region as well, fueled by increased cancer awareness and healthcare investments in countries like China and India.

ML is a disease of the future

Historically, treatment for AML was a combination of chemotherapy and the rigorous demands of a stem cell transplant. Yet, with a high median age at diagnosis and poor treatment outcomes, AML presents a pressing need for new treatment options. As companies are finding new ways to fight the disease and keep the current treatments in the pipeline, a bright future for AML is on the horizon.